{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:15:46Z","timestamp":1784200546188,"version":"3.55.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rituximab and obinutuzumab share the CD20 target but are used across distinct B-cell non-Hodgkin lymphoma (B-NHL) subtypes, treatment backbones, and clinical eras. Their real-world adverse event (AE) reporting patterns remain incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To characterize AE reporting patterns for rituximab and obinutuzumab in B-NHL using FAERS, evaluate signal retention across histological subtype and calendar-period strata and after COVID-associated report exclusion, and describe serious outcome reporting patterns during the common-market period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FAERS reports listing rituximab or obinutuzumab as the primary suspect drug with B-NHL indications from January 2004 to December 2024 were extracted. Disproportionality signals were evaluated using reporting odds ratios (RORs) and Bayesian Confidence Propagation Neural Network (BCPNN)-derived information components (ICs). Pooled B-NHL analyses identified candidate System Organ Class (SOC)- and Preferred Term (PT)-level reporting signals. Candidate signals were further evaluated across histological subtype and calendar-period strata and in a sensitivity analysis excluding reports containing COVID-associated PTs. Multivariable logistic regression assessed serious outcome reporting during the common-market period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In pooled B-NHL analyses, both drugs showed overlapping SOC-level reporting domains, including hematologic, infection-related, respiratory, vascular, and hepatobiliary disorders. Infusion related reaction was the most uniformly retained PT-level signal for both drugs, whereas cytopenia-related hematologic signals showed broad but non-uniform retention. Infection-related, respiratory, and neoplasm-related findings required contextual interpretation according to reporting era, histological subtype, component PT heterogeneity, or survivorship background. Most pooled candidate clinical PT-level signals remained signal-positive after exclusion of COVID-associated reports. Obinutuzumab reports had higher adjusted odds of serious outcome reporting during 2014\u20132019 (aOR 1.59, 95% CI 1.42\u20131.77) but not during 2020\u20132024 (aOR 1.03, 95% CI 0.94\u20131.12), with a significant drug-by-period interaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FAERS reports involving rituximab and obinutuzumab in B-NHL showed overlapping AE reporting domains, but pooled signals differed in retention across clinical and reporting contexts. Infusion related reaction was the clearest consistently retained PT-level finding, whereas cytopenia-related hematologic events formed a broad but non-uniform reporting domain. Signal-retention analyses may help prioritize pharmacovigilance hypotheses and setting-specific AE monitoring, but these reporting patterns require validation in longitudinal data sources and should not be interpreted as causal or direct comparative safety estimates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1855113","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:50:59Z","timestamp":1784199059000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse event reporting patterns of rituximab and obinutuzumab in B-cell non-Hodgkin lymphoma: a FAERS pharmacovigilance study"],"prefix":"10.3389","volume":"17","author":[{"given":"Weihao","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Shantou University Medical College","place":["Shantou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Shantou University Medical College","place":["Shantou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Shantou University Medical College","place":["Shantou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuebin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Shantou University Medical College","place":["Shantou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"B1","unstructured":"Non-Hodgkin Lymphoma - Cancer Stat Facts"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)02705-8","article-title":"B-cell non-Hodgkin lymphomas","volume":"403","author":"Silkenstedt","year":"2024","journal-title":"Lancet (London England)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3324\/haematol.2020.274258","article-title":"Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma","volume":"107","author":"Ma","year":"2022","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/lymphatics2010002","article-title":"A review of anti-CD20 antibodies in the management of B-cell lymphomas","volume":"2","author":"Mahadevia","year":"2024","journal-title":"Lymphatics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2016.08.011","article-title":"Anti-CD20 antibody treatment of non-Hodgkin lymphomas","volume":"172","author":"Engelhard","year":"2016","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.02.009","article-title":"Rituximab resistance","volume":"24","author":"Rezvani","year":"2011","journal-title":"Best Pract Res Clin Haematology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2828","article-title":"Obinutuzumab-related adverse events: a systematic review and meta-analysis","volume":"39","author":"Amitai","year":"2021","journal-title":"Hematological Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41598-021-82841-w","article-title":"Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20(+) B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis","volume":"11","author":"Luo","year":"2021","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05306-2","article-title":"Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma-a real-world multicenter retrospective cohort study","volume":"102","author":"Berger","year":"2023","journal-title":"Ann Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-9-4","article-title":"Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs","volume":"9","author":"Aagaard","year":"2009","journal-title":"BMC Clin Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0334317","article-title":"Safety assessment of obinutuzumab: Real-world adverse event analysis based on the FAERS and JADER databases from 2013 to 2025","volume":"20","author":"Li","year":"2025","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2025.08.001","article-title":"Anticancer drugs associated with tumor lysis syndrome: Insights from the US Food and Drug Administration Adverse Event Reporting System","volume":"47","author":"Wang","year":"2025","journal-title":"Clin Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01308-0","article-title":"Tumor lysis syndrome with CD20 monoclonal antibodies for chronic lymphocytic leukemia: Signals from the FDA Adverse Event Reporting System","volume":"43","author":"Xia","year":"2023","journal-title":"Clin Drug Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1159\/000549124","article-title":"Drug-induced interstitial lung disease: A real-world pharmacovigilance study based on an adverse event reporting system","volume":"105","author":"Cui","year":"2026","journal-title":"Respiration; Int Rev Thorac Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"43048","DOI":"10.1038\/s41598-025-26999-7","article-title":"A real-world safety analysis of infection-related adverse events associated with belimumab, rituximab, and TNF inhibitors using the FAERS database","volume":"15","author":"Sisi","year":"2025","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2026.107158","article-title":"Ocular toxicity associated with anti-CD20 monoclonal antibodies: A pharmacovigilance analysis using the FAERS database","volume":"109","author":"Kuang","year":"2026","journal-title":"Multiple Sclerosis Related Disord"},{"key":"B22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2473","article-title":"Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events","volume":"25","author":"Nor\u00e9n","year":"2006","journal-title":"Stat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1017889","article-title":"Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)","volume":"13","author":"Ma","year":"2022","journal-title":"Front Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000919","article-title":"Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: Final results from the GALLIUM study","volume":"7","author":"Townsend","year":"2023","journal-title":"HemaSphere"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910301)67:5<1389::aid-cncr2820670519>3.0.co;2-q","article-title":"Clinical significance of hematologic parameters in non-Hodgkin's lymphoma at diagnosis","volume":"67","author":"Conlan","year":"1991","journal-title":"Cancer"},{"key":"B28","article-title":"Bone marrow and peripheral blood changes in non-Hodgkin's lymphoma","volume":"41","author":"Lim","year":"2000","journal-title":"Singapore Med J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm541","article-title":"Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma","volume":"19","author":"Ziepert","year":"2008","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(19)30253-4","article-title":"Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations","volume":"7","author":"Tambaro","year":"2020","journal-title":"Lancet Haematology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.29.1112","article-title":"Second Malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006369","article-title":"Incidence and time trends of second primary Malignancies after non-Hodgkin lymphoma: a Swedish population-based study","volume":"6","author":"Joelsson","year":"2022","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv616","article-title":"Rituximab and risk of second primary Malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis","volume":"27","author":"Fleury","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1855113\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:51:01Z","timestamp":1784199061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1855113\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2026.1855113"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1855113","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"article-number":"1855113"}}